Back to search results

Observational Study of CAR-T Therapy in Older Patients with Lymphoma

This study is looking at how older patients (age 60 and above) with certain types of lymphoma, including B-Cell Lymphoma and DLBCL NOS, respond to CAR-T cell therapy. It also examines how this treatment affects their daily life and overall well-being. This is an observational study, meaning you will receive standard CAR-T treatment, and researchers will collect information on your activities of daily living, mental function, and mood. The goal is to understand the experiences of 154 older patients over one year. The study will measure how many participants complete all assessments before their disease worsens or they pass away.

Study design
This is an observational study with a planned enrollment of 154 participants. It is not a treatment study, but rather focuses on collecting information about patients receiving standard CAR-T therapy.
What's involved
You would participate in assessments like activities of daily living, mental function tests (Mini-Cognition test), and a depression scale (Geriatric Depression Scale). These assessments are done at required visits.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for one year to see how many complete all required assessments.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04300998

Study of CAR-T Therapy in Older Patients

Recruiting
Not specifiedAges 60+Observational
Memorial Sloan Kettering Cancer Center
~154 participants
Updated 2026-04-07 on ClinicalTrials.gov
What's tested:Activities of Daily Living/ADLsInstrumental Activity of Daily LivingTimed Up and GoCognitionGeriatric Depression ScaleSocial Support

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants who complete all required assessment visits prior to disease progression or death
Measured over 1 year

Conditions

Lymphoma
Refractory B-Cell Lymphoma
Lymphoma, B-Cell
DLBCL NOS
High-grade B-cell Lymphoma
Multiple Myeloma

Explore related trials

Diffuse Large B-Cell LymphomaHigh Grade B-Cell LymphomaLymphomaMultiple Myeloma

NCT04300998

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Memorial Sloan Kettering Cancer Center

    New York, New Yorkstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Richard Lin, MD, PhD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Richard Lin, MD, PhD
[email protected]
646-608-2646
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

are ≥60 years old (all cohorts)
have pathologically confirmed, relapsed refractory lymphoid malignancy or plasma cell disorder receiving a commercial CAR T-cell product (all cohorts)
able to speak and understand English (cohort 1 and 4 only)
have a MoCA score of less than 26 out of 30 during the GA visit by a geriatrician prior to CAR T-cell treatment (cohort 4 only)

Exclusion

Any prior commercial or investigational CAR T therapy (all cohorts)
Current diagnosis of major Axis I psychiatric disorder (DSM-IV), major depression, bipolar disorder, or schizophrenia, as per medical records or patient report (cohort 1 only)
History of a neurological disorder, neurodegenerative disease, or traumatic brain injury with loss of consciousness (\>60 minutes), as per medical records or patient report (cohort 1 only)
Current ongoing substance abuse and/or history of substance abuse, as per medical records or patient report (cohort 1 only)
History of CNS disease (cohort 4 only)

What this trial measures

  • Number of participants who complete all required assessment visits prior to disease progression or death1 year

    Participants who complete all assessment visits prior to disease progression or death will be considered as a success for a feasibility endpoint.